-
Product Insights
NewNet Present Value Model: Provention Bio Inc’s PRV-3279
Empower your strategies with our Net Present Value Model: Provention Bio Inc's PRV-3279 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Provention Bio Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Provention Bio Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Thematic Analysis
Pharma M&A Deals 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in 2023 in the Pharma Sector
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emapalumab in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Emapalumab in Systemic Lupus Erythematosus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Emapalumab in Systemic Lupus Erythematosus Drug Details: Emapalumab (Gamifant) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pacritinib in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pacritinib in Graft Versus Host Disease (GVHD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pacritinib in Graft Versus Host Disease (GVHD) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRV-101 in Enterovirus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRV-101 in Enterovirus Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PRV-101 in Enterovirus Infections Drug Details:PRV-101 is under development for the prevention of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PRV-101 in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRV-101 in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRV-101 in Type 1 Diabetes (Juvenile Diabetes) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aflibercept Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aflibercept Biosimilar in Wet (Neovascular /...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ondansetron Hydrochloride in Alcohol Addiction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ondansetron Hydrochloride in Alcohol Addiction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Ondansetron Hydrochloride in Alcohol AddictionDrug Details:Ondansetron (AD-04) is under development for the...